


PRODUCT INFORMATION



Pixantrone (maleate)

Item No. 20055

CAS Registry No.: 144675-97-8
Formal Name: 6,9-bis[(2-aminoethyl)amino]-benz[*g*]isoquinoline-5,10-dione, dimaleate
Synonym: BBR 2778
MF: C₁₇H₁₉N₅O₂ • 2C₄H₄O₄
FW: 557.5
Purity: ≥95%
UV/Vis.: λ_{max}: 214, 324, 513 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Pixantrone (maleate) is supplied as a crystalline solid. A stock solution may be made by dissolving the pixantrone (maleate) in the solvent of choice. Pixantrone (maleate) is soluble in the organic solvent DMSO, which should be purged with an inert gas, at a concentration of approximately 1 mg/ml.

Description

Pixantrone is a DNA topoisomerase II inhibitor.¹ It induces SV40 DNA cleavage in the presence of mouse topoisomerase II and induces DNA single-strand breaks in NCI H187 cells in a concentration-dependent manner. Pixantrone is cytotoxic to L1210 leukemia cells as well as doxorubicin-sensitive and -resistant LoVo colon adenocarcinoma cells (IC₅₀ = 0.01, 0.24, and 7.2 μg/ml, respectively).² It decreases disease severity in a rat model of myasthenia gravis induced by immunization with the *T. californica* acetylcholine receptor (AChR) when administered at a dose of 8.12 mg/kg once per week for six weeks.³ Formulations containing pixantrone have been used in the treatment of non-Hodgkin B cell lymphoma.

References

1. De Isabella, P., Palumbo, M., Sissi, C., *et al.* Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. *Mol. Pharmacol.* **48(1)**, 30-38 (1995).
2. Krapcho, A.P., Petry, M.E., Getahun, Z., *et al.* 6,9-Bis[(aminoalkyl)amino]benzo[*g*]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: Synthesis and antitumor evaluations. *J. Med. Chem.* **37(6)**, 828-837 (1994).
3. Marolda, R., Ruocco, C., Cordiglieri, C., *et al.* Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis. *J. Neuroimmunol.* **258(1-2)**, (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM